Cheat Sheet For Pharmacology Aesthetic

What People Actually Need When They're Studying Aesthetic Pharmacology

Most cheat sheets you find online are just rehashed drug monographs scraped from prescribing information. They look thorough but they don't help you when you're standing at a patient's face trying to decide between 20 units of onabotulinumtoxinA and 25 units of abobotulinumtoxinA, or when a patient comes in five days later with a bruise the size of a saucer after a buccal filler session and you need to know exactly how much hyaluronidase to prepare. I built my own because nothing out there actually covered the stuff that matters in real practice.

Here is the structure that works. Not because it is clever, but because it mirrors the way you actually think during a consultation and during complications. The core of any useful reference is a comparison table for the neurotoxins. I keep onabotulinumtoxinA, incobotulumtoxinA, abobotulinumtoxinA, and rimabotulinumtoxinB side by side with their unit-to-unit conversion ratios, onset times, peak effects, and duration ranges. The conversion ratios are the part everyone gets wrong. The 1:1 myth between units of different products is dangerous. My table uses the widely accepted approximate equivalences: 1 unit of onabotulinumtoxinA equals roughly 2.5 to 3 units of abobotulinumtoxinA, and 1 unit of onabotulinumtoxinA equals about 20 to 25 units of rimabotulinumtoxinB. I note clearly that these are clinical approximations, not hard science, and that manufacturer guidelines should always override conversions when they differ. Next section is hyaluronic acid fillers. I organize them by crosslinking technology and rheological properties, not just brand names. G prime, cohesivity, and viscosity determine whether a product is suited for deep structural placement or superficial fine-line correction. Beginners often pick a filler based on marketing rather than rheology. I list the major HA products with their approximate G prime values and recommended injection planes. A product with a G prime above 40 Pa like Juvéderm Voluma or Restylane Lyft belongs in the deep dermal to subcutaneous plane. A product with a G prime below 20 Pa like certain superficial Juvéderm Volbella formulations belongs in the papillary dermis. This matters more than the brand name.

The complications section is where most cheat sheets fail completely. They list adverse events but not the decision tree. I include a practical flow: if a patient develops blanching and mottling immediately after injection, that is vascular compromise until proven otherwise. You do not wait to see if it gets better. You apply warm compresses, massage the area gently, and prepare hyaluronidase immediately. The standard reconstitution I use is 150 units of hyaluronidase per mL of sterile water, and for an emergency reversal I typically inject 50 to 150 units directly into the affected area, then another 50 to 150 units subcutaneously around the site. I repeat every 24 hours if needed. This is not theoretical. I had a case last year where a patient developed a wedge-shaped area of blanching in the glabella after what I thought was a straightforward line treatment. The blush came back after the first hyaluronidase injection but returned worse within 18 hours. I escalated to 200 units of hyaluronidase in a single session split across three injection points in the zone, and the skin settled within four hours. Waiting would have been a mistake. Antidotes and rescue medications deserve their own section. Hyaluronidase for filler emergencies is obvious. Naloxone for opioid overreaction during lengthy procedures is standard. Flumazenil for benzodiazepine reversal is rarely used in aesthetic settings but worth noting if you are doing sedation. Steroids for severe allergic reactions, diphenhydramine for urticaria, epinephrine for anaphylaxis. I list the doses I actually reach for, not the textbook maximums that would overwhelm a typical aesthetic clinic setup. Local anesthetic pharmacology is another section people skip. Lidocaine dosing limits matter. The maximum recommended dose of lidocaine with epinephrine is 7 mg per kg of body weight. For a 70 kg patient that is 490 mg total. Most pre-filled syringes contain 1.3 mL of 2% lidocaine, which is 26 mg per syringe. That means you could theoretically use nearly 19 syringes before hitting the limit, but clinical context matters more than the raw number. Combining lidocaine with bupivacaine extends duration but changes the toxicity profile. Bupivacaine maximum is 2.5 mg per kg with epinephrine. Mixing the two requires careful volume accounting so you do not accidentally exceed either limit.

How I Actually Use This During Work

I keep a laminated one-page version at my workstation and a digital copy on my phone. The laminated sheet has the neurotoxin comparison, the filler rheology chart, and the complication algorithm. The digital copy has the full antidote dosing and the local anesthetic calculations. When I am consulting, I reference the neurotoxin table to adjust dosing based on muscle mass and previous response. When I am injecting fillers, I check the G prime chart to confirm the product I pulled from the fridge matches the indication. When something goes wrong, which it inevitably does at some point, I go straight to the complication algorithm and follow it step by step instead of panicking. One thing I added after years of practice is a section on patient-specific pharmacokinetic variables. Age, liver function, renal function, and concurrent medications all affect how a patient responds. I keep a reminder column for CYP450 interactions with common aesthetic medications. St. John's wort induces CYP3A4 and can accelerate the metabolism of certain sedatives. Grapefruit juice inhibits CYP3A4 and has the opposite effect. These are small details that compound over time and are rarely covered in standard training programs.

What This Approach Does Not Do Well

A cheat sheet cannot replace hands-on training or ongoing continuing education. It cannot capture every edge case because new formulations and combination protocols emerge regularly. The unit conversion charts for neurotoxins are approximations based on clinical studies that vary in methodology. Different physicians in different countries use different conversion factors. There is no universal standard. If you rely on a single source without cross-checking, you will encounter discrepancies. I cross-reference the prescribing information from each manufacturer alongside peer-reviewed comparative studies whenever I update my sheet. Another limitation is that a static document cannot adapt to your own clinical experience. You will develop personal preferences and observational patterns that no published guide will reflect. I add annotations to my sheet as I learn from each case. A patient who consistently requires higher units in the corrugator muscles due to hypertrophy becomes a note on the neurotoxin page. A filler product that caused unexpected swelling in a particular anatomical zone becomes a warning next to that product's entry. The value of the sheet grows with use, but only if you maintain it. If you want a starting point, most professional aesthetic medicine organizations publish downloadable pharmacology references. The American Academy of Aesthetic Medicine and similar bodies have guides that cover the fundamentals. I do not host my personal sheet because it evolves constantly and would be outdated within months if shared as a static file. What I can say is that the structure I described above is what separates a functional reference from a pile of copied drug facts. Build it around decision-making, not memorization. Include the conversions, the rheology, the complication algorithms, and the antidote doses. Leave out the fluff. That is all there is to it.